Overview

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and tolerability of PRI-724 in patients with HCV-induced cirrhosis.
Phase:
Phase 1
Details
Lead Sponsor:
Komagome Hospital
Collaborator:
Prism Pharma Co., Ltd.